Molecular Partners AG presented updated data from its Phase 1/2a MP0533 trial at the 67th American Society of Hematology (ASH) meeting in Orlando, Florida. The poster covered cohorts 8 and 9, in which 54 patients were treated. Of the 48 evaluable patients, 8 achieved a response—five composite complete responses and three morphologic leukemia‑free states—highlighting early antitumor activity in a heavily pre‑treated AML population.
The densified dosing schedule used in the trial was well tolerated and produced higher serum exposure in cycle 1, supporting the company’s plan to test MP0533 in both relapsed/refractory and front‑line settings. One patient in cohort 8 has remained in complete remission for more than a year, and a patient in cohort 9 has been on the trial for four months, underscoring the durability of the response in this early‑stage study.
Management emphasized that the data reinforce MP0533’s unique multi‑targeting mechanism, which engages CD33, CD123, CD70 on leukemic cells and CD3 on T cells. CEO Patrick Amstutz noted that the trial “demonstrates the safety and efficacy of a tetraspecific T‑cell engager in AML” and that the company will report additional data on optimized dosing and patient selection in the coming months. The company plans to advance MP0533 to a Phase 2 study, with the goal of expanding its use in combination with standard therapies.
Financially, Molecular Partners reported Q3 2025 results on October 30 2025 with an EPS of –$0.41 versus an estimate of –$0.46, a modest beat driven by disciplined cost management amid a zero‑revenue quarter. The company’s cash runway remains a concern, as it has faced declining revenue and negative profitability margins in prior periods. The updated clinical data provide a potential catalyst for future funding and partnership opportunities, but the company’s balance sheet still requires careful monitoring.
Analysts reacted to the ASH presentation by lowering their price targets and maintaining a neutral stance. The mixed market reaction reflects investor caution over the company’s financial position, despite the encouraging clinical signals. The data suggest that while MP0533 shows promise, the broader commercial viability and funding strategy remain key questions for stakeholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.